Pharmaceuticals Singapore

Singapore Radiopharmaceuticals Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Singapore Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Singapore · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $9.9 Mn Placeholder estimate
Estimate 2025 $10.9 Mn 0.1% of the global market
Projected 2034 $27.8 Mn 153.7% Adds $16.8 Mn over 9 forecast years
CAGR 2025–2034 10.9% Faster than 63% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Singapore is 0.12% of the global market.
  • In APAC, the largest is China at $813.1 Mn.
  • Fastest growing: India at 12.8% a year.
  • Singapore ranks 9th of 10 by size in APAC.

Market size projection

Singapore

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$16.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Radiopharmaceuticals Market market size by year, Singapore
YearMarket sizeChange that yearSince 2025
2024 (estimate) $9.9 Mn — —
2025 (base) $10.9 Mn +$1.1 Mn —
2026 (forecast) $12.1 Mn +$1.2 Mn +10.9%
2027 (forecast) $13.5 Mn +$1.3 Mn +23%
2028 (forecast) $14.9 Mn +$1.5 Mn +36.4%
2029 (forecast) $16.6 Mn +$1.6 Mn +51.3%
2030 (forecast) $18.4 Mn +$1.8 Mn +67.7%
2031 (forecast) $20.4 Mn +$2.0 Mn +86%
2032 (forecast) $22.6 Mn +$2.2 Mn +106.3%
2033 (forecast) $25.0 Mn +$2.5 Mn +128.8%
2034 (forecast) $27.8 Mn +$2.7 Mn +153.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Singapore Radiopharmaceuticals Market Analysis at a glance
Market size, 2025$10.9 Mn placeholder estimate
Forecast, 2034$27.8 Mn placeholder estimate
Growth (CAGR), 2025–203410.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, isotope and end user (see all)
Key playersNovartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and 1 more (see all)
Regulator in SingaporeHSASource: Health Sciences Authority. Checked 14 Nov 2026.
Active clinical trials5 in SingaporeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Singapore Radiopharmaceuticals Market Analysis Executive Summary

Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.

Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).

Bar chart: Singapore Radiopharmaceuticals market size, 2024–2034, placeholder estimates. $9.9 Mn in 2024, $10.9 Mn in 2025 and $27.8 Mn in 2034, 10.9% CAGR.
Singapore Radiopharmaceuticals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Singapore Radiopharmaceuticals Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.

Competitive Landscape for Radiopharmaceuticals Market in Singapore

The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Radiopharmaceuticals Market in Singapore

Radiopharmaceuticals in Singapore: rules, payment and research

Therapeutic products need registration with the Health Sciences Authority (HSA).⁠[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.⁠[2] ClinicalTrials.gov lists 5 studies on Radiopharmaceuticals that are recruiting, active or about to start in Singapore.⁠[3]

[1] Health Sciences Authority. Checked 14 Nov 2026.

[2] CPF Board, MediShield Life. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.

Clinical trials

5 active trials in Singapore

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Novartis AG 19 active trials on ClinicalTrials.gov (opens in a new tab)
  2. AstraZeneca 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Eli Lilly and Company 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Fusion Pharmaceuticals Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. AC Immune (Switzerland) 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Radiopharmaceuticals in context

Singapore compared

  • Health spending per person: 3,922 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.83 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.2% of people (2025). World: 10.4% of people (2025). 7th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Radiopharmaceuticals market in Singapore?
Placeholder estimate: about $10.9 Mn in 2025, rising to about $27.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Radiopharmaceuticals market in Singapore growing?
Placeholder estimate: about 10.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Radiopharmaceuticals market report cover?
The report splits the market by type (Diagnostic, Therapeutic), isotope (Lutetium-177, Actinium-225, Fluorine-18, Technetium-99m and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Radiopharmaceuticals market?
Key players include Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and GE Healthcare.
What is driving the Radiopharmaceuticals market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Who regulates Radiopharmaceuticals in Singapore?
Therapeutic products need registration with the Health Sciences Authority (HSA). Source: Health Sciences Authority. Checked 14 Nov 2026.
How is healthcare paid for in Singapore?
MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts. Source: CPF Board, MediShield Life. Checked 14 Nov 2026.
How many clinical trials on Radiopharmaceuticals are running in Singapore?
5 studies are recruiting, active or about to start in Singapore, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
How much research is published on Radiopharmaceuticals?
PubMed lists 2,809 papers on Radiopharmaceuticals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Singapore

See all

Related on oncology

See the topic